Varicella vaccination in Italy and Germany - different routes to success: a systematic review.
Chickenpox
/ epidemiology
Chickenpox Vaccine
/ administration & dosage
Disease Notification
/ methods
Germany
/ epidemiology
Health Care Costs
/ statistics & numerical data
Hospitalization
/ economics
Humans
Immunization Programs
Italy
/ epidemiology
Measles-Mumps-Rubella Vaccine
/ administration & dosage
Vaccination
/ methods
Vaccines, Combined
/ administration & dosage
Burden of disease
effectiveness
epidemiology
germany
health economics
immunization coverage
italy
surveillance
systematic review
varicella vaccine
Journal
Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
25
9
2020
medline:
1
4
2021
entrez:
24
9
2020
Statut:
ppublish
Résumé
Italy (in pilot regions) and Germany (nationwide) were the first European countries to introduce universal varicella vaccination (UVV) programs. A systematic review was performed to assess varicella epidemiology before UVV programs and the impact of 1-dose and 2-dose UVV programs in Italy and Germany. Italy implemented 1- or 2-dose UVV programs successively in eight pilot regions between 2003 and 2011 and nationwide in 2017. Germany implemented 1- and 2-dose UVV programs in 2004 and 2009, respectively. While Italy had two nationwide surveillance systems in place for varicella in the pre-vaccination era, in Germany, a mandatory notification system for varicella was only introduced in the New Federal States 2 years before the 1-dose UVV implementation. Substantial reductions in moderate/severe varicella and varicella-related hospitalization incidence occurred during the 1-dose era. Further reductions were reported in Italy and Germany after the recommendation of a second dose in a long or short schedule, respectively. Different benefit-risk evaluations of a tetravalent varicella-containing vaccine (MMRV) used as a first dose led to different recommendations (MMRV versus MMR+V) in these countries. Vaccination strategies in both countries tailored to country-specific needs and goals led to a reduction in varicella-related health care hospitalization costs.
Identifiants
pubmed: 32969747
doi: 10.1080/14760584.2020.1825947
doi:
Substances chimiques
Chickenpox Vaccine
0
Measles-Mumps-Rubella Vaccine
0
Vaccines, Combined
0
measles, mumps, rubella, varicella vaccine
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM